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KEY POINTS Q6
 Liver-related mortality is the third cause of death in patients with nonalcoholic Q7fatty liver
disease (NAFLD) and is significantly higher in patients with nonalcoholic steatohepatitis
(NASH) compared with patients with simple steatosis (7.3% vs 0.9% respectively) within
the first 15 years of follow-up.
 The presence and severity of fibrosis on liver biopsy is currently the best indicator of long-
term liver outcomes in patients with NAFLD.
 The rate of fibrosis progression is at around 1 stage every 6 to 15 years in patients with
NASH but is reduced by half in patients with simple steatosis. However, some patients
with NAFLD, also with simple steatosis, can progress rapidly to clinically significant
fibrosis.
 Patients with NAFLD with cirrhosis have lower rates of liver-related complications but
similar overall mortality as compared with patients with hepatitis C virus because of a
higher incidence of cardiovascular events.
 Hepatocellular carcinoma incidence is growing in patients with NAFLD with or without
cirrhosis, particularly among those with multiple metabolic risk factors.Q8 Q9INTRODUCTION
The 3 leading causes of death in patients with nonalcoholic fatty liver disease (NAFLD)
in descending order are cardiovascular disease, cancer, and liver disease. Although
the extrahepatic complications of NAFLD are described elsewhere, this section is
focused on the potential liver-related morbidity and mortality that, along with the large
prevalence and increasing incidence of this disease in the general population, clearly
forecast the future impact of NAFLD on health care.The authors have nothing to disclose.
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99The burden of data on the liver-related complications of NAFLD comes from studies
addressing both the clinical course and the progression of liver damage through
paired liver biopsies, but tackling the natural history of NAFLD is one of the most diffi-
cult challenges for researchers. On one hand, the variety of criteria used to define
NAFLD from the clinical point of view (abnormal liver enzymes, hepatic ultrasound,
indices of liver fat, and liver biopsy), coupled with the lack of sensitivity and specificity
of most of the tests used and the composite nature of NAFLD outcomes, has
hampered most clinical studies. On the other hand, studies based on repeat biopsies
are limited by sampling variability and by the lack of consensus on what is the best
definition of nonalcoholic steatohepatitis (NASH). Several scoring systems have
been described to classify liver histology in adults with NAFLD.1–3 The NASH Clinical
Research Network (CRN) classification is the most frequently used in recent studies;
however, the NAFLD Activity Score (NAS) has often been used as a surrogate for the
diagnosis of NASH, although it is not designed for it but rather for crude evaluation of
disease severity, once the diagnosis has been established by the overall pathologic
assessment. The prospectively designed Steatosis-Activity-Fibrosis score2 has
been recently introduced. Despite these caveats, the threat that NAFLD is going to
replace chronic hepatitis C as major cause of liver morbidity and mortality should
be no longer overlooked.LIVER DISEASE PROGRESSION IN SIMPLE STEATOSIS AND NONALCOHOLIC
STEATOHEPATITIS
Major prospective cohort studies have been derived from Western populations,
whereas data in Asian, African, and Latin American populations are limited
(Table 1). The overall long-term mortality of Western patients with the whole spec-
trum of NAFLD is 34% to 69% higher than the general population of the same age
and sex within 15 years of follow-up and is mostly due to cardiovascular disease.4
In a community-based study of 420 patients from the United States, liver disease
was the third leading cause of death in patients with NAFLD, as compared with the
13 leading causes of death in the general Minnesota population.5 However, only 21
(5%) patients were diagnosed with cirrhosis, and 3.1% developed liver-related com-
plications, including one requiring liver transplantation (LT) and 2 developing hepato-
cellular carcinoma (HCC). Higher mortality was associated with age (hazard ratio [HR]
per decade 2.2; 95% confidence interval [CI] 1.7–2.7), impaired fasting glucose (HR
2.6; 95% CI 1.3–5.2), and cirrhosis (HR 3.1; 95% CI 1.2–7.8).
Importantly, there is a prognostic association between the presence of NASH, the
stage of liver disease (higher fibrosis stage), and the long-term prognosis of patients
with NAFLD. In patients with NASH compared with patients with simple steatosis,
both the prevalence of cirrhosis development (10.8% vs 0.7%, respectively) and
the liver-related mortality are significantly higher (7.3% vs 0.9%) within the first
15 years of follow-up.10 These findings have been repeatedly confirmed. In a land-
mark study,9 although just 5% of the 129 patients with biopsy-proven NASH enrolled
went on to develop end-stage liver disease, including 3 patients with HCC, liver-
related mortality was increased 10-fold compared with the reference population.
However, in patients with simple steatosis (or steatosis with mild inflammation/cellular
injury), the overall and liver-related mortality risk was not different. In the long-term
follow-up studies available thus far, only 1% of patients with simple steatosis
developed cirrhosis and died a liver-related death after a mean 15.6 years of
follow-up, compared with 11% of those with NASH having or developing cirrhosis,
and 7.3% of those with NASH dying of a liver-related cause after a similar period ofCLD798_proof ■ 3 November 2015 ■ 11:00 am
Table 1
Prevalence of cirrhosis in patients with NAFLD diagnosed by liver biopsy
Author (Year) Diagnosis Number
Cirrhosis
Prevalence (%) Follow-up (y) Main Findings
Teli et al,6 1995 Q17Bland steatosis 40 0 9.6 There was no progression to NASH/cirrhosis.
Dam-Larsen et al,7
2004
Bland steatosis 109 1 16.7 Patients with NAFLD have a benign clinical course without excess
mortality.
Matteoni et al,8 1999 NAFLD 98 20 8.3 Poor outcomes are more frequent in patients with NASH.
Adams et al,5 2005 NAFLD 420 5 7.6 Mortality among patients with NAFLD is higher than the general
population.
Ekstedt et al,9 2006 NAFLD 129 7.8 13.7 NAFLD with elevated ALT/AST is associated with a significant risk of
developing end-stage liver disease. Survival is lower in patients
with NASH.
So¨derberg et al,10
2010
NAFLD 143 9 28.0 Patients with NASH are at increased risk of death compared with the
general population.
Lee,11 1989 NASH 39 16.3 3.8 NASH has the potential to progress into cirrhosis.
Powell et al,12 1990 NASH 42 7 4.5 NASH should be recognized as a further cause of CC.
Evans et al,13 2002 NASH 26 4 8.7 There is no evidence of progressive chronic liver injury in patients
with NASH.
Hashimoto et al,14
2005
NASH septal
fibrosis/cirrhosis
89 48 3.7 The most important consequence of patients with NAFLD with
advanced fibrosis was HCC.
Sanyal et al,15 2006 Cirrhotic-stage NASH 152 100 10.0 NASH-cirrhosis has a lower mortality rate compared with HCV-
cirrhosis but a greater CV mortality.
Ascha et al,16 2010 Cirrhotic-stage NASH 195 100 3.2 Patients with NASH-cirrhosis have an increased risk of HCC.
Bhala et al,17 2011 NASH septal
fibrosis/cirrhosis
247 54 7.4 Patients with NAFLD-cirrhosis have lower rates of liver-related
complications and HCC than patients with HCV infection but similar
overall mortality.
Stepanova et al,18
2013
NASH 289 NA 12.5 Patients with NASH have a higher risk of liver-related mortality than
non-NASH.
Abbreviations: ALT/AST, alanine/aspartate aminotransferase Q18; CC, cryptogenic cirrhosis; CV, cardiovascular; HCC, hepatocellular carcinoma; NA, not available. Q
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201follow-up,4 leading to the concept that simple steatosis is a relatively “benign state,”
whereas NASH represents the form of NAFLD potentially progressive to cirrhosis and
its complications (Fig. 1).
However, it is important to discriminate which of the histologic features of NASH
are true determinants of long-term prognosis. In a cohort of 256 Swedish subjects,
after a follow-up of up to 28 years, 40% of the 118 subjects with a histologic diagnosis
of NAFLD died.10 Compared with the total Swedish population, adjusted for sex, age,
and calendar period, subjects with bland steatosis exhibited a 55% increased mor-
tality and subjects with NASH 86%. Quite surprisingly, the study reported similar
overall-related and liver-related mortality between the groups with and without defin-
itive NASH (classified with the NASH CRN scoring system). However, 67% of patients
classified as non-NASH in this study had liver fibrosis or even well-established
cirrhosis, as fibrosis is not included in the NAS score. Thus, most likely the difference
between the prognosis of NASH and simple steatosis is due to the greater likelihood
of fibrosis being present in patients with NASH. This concept is supported by several
studies. A more recent survey19 conducted on 209 patients with NAFLD with a me-
dian 12 years of follow-up showed the presence of NASH correlated with liver mor-
tality only when fibrosis was included in its definition, and the risk was highest with
bridging fibrosis and cirrhosis (HR 5.68, 95% CI 1.5–21.5). Thus, it would seem likely
that the presence and severity of fibrosis at liver biopsy would be the most important
histologic determinant of long-term prognosis. Further evidence comes from recent
studies demonstrating that noninvasive scoring systems correlating with the degree
of fibrosis are capable of predicting liver-related events, LT, and death in patients with
NAFLD.20
The rate of fibrosis progression in NAFLD is generally slow, and regression may also
occur; but a subset of patients either with NASH or simple steatosis can develop
severe liver damage quite rapidly (see Fig. 1). In a systematic review and meta-anal-
ysis21 including 411 patients with biopsy-proven NAFLD (63% with NASH), over
2145.5 person-years of follow-up, 33.6% had fibrosis progression, 43.1% had stable
fibrosis, and 22.3% had an improvement in fibrosis stage. The annual fibrosis progres-
sion rate in patients with NASH was doubled compared with that in patients withFig. 1. Risk stratification for fibrosis progression in NAFLD.
CLD798_proof ■ 3 November 2015 ■ 11:00 am
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252simple steatosis; overall, one stage of fibrosis progression in patients with NASH
occurred over 7.1 years in NASH versus 14.3 years in those with simple steatosis.
However, the proportion of fibrosis progressors who moved from stage 0 to advanced
(stage 3 or 4) fibrosis (rapid progressors) was identical in the 2 histologic subgroups
(17% of patients with steatosis and 18% of patients with NASH). Similarly, a recent
study has challenged the current concept that simple steatosis is a benign disease
and cannot progress to significant liver damage. In a cohort of 108 patients from
the United Kingdom with serial biopsies,22 81 had a baseline histologic diagnosis of
NASH (75%) and 27 (25%) of NAFLD. The mean annual rate of fibrosis progression
was 0.08 0.25 stages. Remarkably, 44% of patients with baseline NAFLD developed
NASH, including 10 patients in which fibrosis worsened over time (3 of 10 progressed
by 1 stage, 5 by 2 stages, and 2 by 3 stages). No difference in the proportion exhibiting
fibrosis progression was found between patients with steatosis or NASH at index bi-
opsy (37% vs 43%), although all patients with steatosis developing fibrosis had also
developed NASH on follow-up biopsy (see Fig. 1). Of note, 44% of the patients with
steatosis developed NASH after a median 8 years of follow-up, suggesting that
NASH usually develops after steatosis. Overall, these data suggest that the necroin-
flammatory damage per se is not as important as fibrosis for the long-term prognosis
of patients with NAFLD and accordingly the major focus of therapy should be in the
resolution of fibrosis rather than of the other histologic features of NASH.RISK FACTORS FOR DISEASE PROGRESSION IN SIMPLE STEATOSIS AND
NONALCOHOLIC STEATOHEPATITIS
Provided that the presence and severity of fibrosis is the key factor determining long-
term, liver-related mortality, the key question is which are the main determinants of
NAFLD progression that can be identified without a liver biopsy. Age, body mass in-
dex (BMI), type 2 diabetes mellitus (T2DM) or metabolic syndrome (MetS), and insulin
resistance assessed by homeostasis model assessment are well-recognized risk fac-
tors for advanced fibrosis in multiple cross-sectional studies; but few of them have
also been examined in longitudinal studies and in relation to their ability to predict
the progression of NAFLD. In the previously cited meta-analysis,21 the presence of
hypertension (odds ratio [OR] 1.94; 95% CI 1.00–3.74) and a low aspartate amino-
transferase (AST)/alanine transaminase (ALT) ratio at the time of baseline biopsy
was associated with the progression of fibrosis, whereas in the most recent study,22
most (80%) of the patients with NAFLD in which fibrosis worsened were diabetic and
had a longer disease duration. Fibrosis progressors had also a significantly lower
platelet count (P 5 .04) and higher AST/ALT ratio (P 5 .04) and Fibrosis 4 (FIB-4)
score (P 5 .02) than nonprogressors. The same study identified the FIB-4 score as
the only significant baseline factor able to predict fibrosis progression, whereas the
presence of T2DM (OR 6.25; CI 1.88–20) and FIB-4 score (OR 3.1; CI 1.4–6.8,
P 5 .004) at the time of follow-up liver biopsy were indicators of the presence of
fibrosis.
Among genetic factors, homozygosity for the patatin-like phospholipase domain-
containing protein (PNPLA3) 148M allele has been associated with a 3.3-fold
increased risk of both NASH and liver fibrosis independent of BMI, T2DM, and stea-
tosis (for NASH) and age, BMI, T2DM, steatosis, and NASH (for fibrosis).23 The as-
sociation between PNPLA3 I148M and the severity of fibrosis in NAFLD has been
almost contemporarily replicated by independent groups in adults24,25 and in the
pediatric population26 and confirmed by a recent meta-analysis.27 Studies on the
ability of genetic and other factors to predict the risk of disease progression areCLD798_proof ■ 3 November 2015 ■ 11:00 am
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303definitely needed, not only in the Western population but also in other developed
and developing countries where the risk of NAFLD is paralleling the economic
development.
LIVER DISEASE PROGRESSION IN NONALCOHOLIC STEATOHEPATITIS–RELATED
CIRRHOSIS
It is well established that patients with severe liver damage are more likely to develop
liver-related complications, and pooled data from long-term (w10 years) follow-up
studies of patients with NAFLD with advanced fibrosis and cirrhosis demonstrate a
16%mortality with 60% of the deaths liver-related compared with only approximately
9% liver-related in long-term (w15 years) follow-up studies of patients with NAFLD
without advanced fibrosis or cirrhosis.4 However, the natural history of cirrhosis due
to NASH has been addressed by only few studies.
In an Australian study of 23 patients with NASH cirrhosis identified from a hospital
database, the 10-year survival rate was 84%. Comparing these patients to subjects
affected by hepatitis C virus (HCV)–related cirrhosis, the study showed no difference
between liver-related deaths or all-cause mortality between the two groups after
adjustment for baseline differences, despite a trend toward improved survival in
NASH.28 In a larger study,15 the 10-year survival in the NASH group was 80.9%,
significantly better than in the HCV controls of similar age, sex, and Child-Pugh score,
principally because of a lower risk of hepatic decompensation in the NASH cohort. In
subjects with NASH-related cirrhosis, ascites was the first and most common clinical
feature of decompensation but occurred at a slower rate than in patients with HCV.
Once ascites developed, the rate of hepatorenal syndrome was similar in the two
groups. Development of varices and the rates of variceal hemorrhage were similar
in NASH-related and HCV-related cirrhosis, whereas the incidence of hepatic en-
cephalopathy was intermediate between that for ascites and variceal hemorrhage.
Remarkably, subjects with NASH-related cirrhosis had a significantly higher rate of
cardiovascular mortality compared with HCV-related cirrhosis. These data have
been corroborated in another independent cohort.16 In a multicenter prospective
study,17 the long-term morbidity and mortality of 247 patients with NAFLD advanced
fibrosis or cirrhosis was compared with 264 patients with HCV cirrhosis. Both cohorts
were Child-Pugh class A and had cirrhosis confirmed by liver biopsy. In the NAFLD
cohort, liver-related complications occurred in 19.4% of cases and deaths or LT in
13.4%, compared with 16.7% and 9.4%, respectively, in the HCV cohort. When
adjusting for baseline differences in age and sex, the cumulative incidence of liver-
related complications was lower in the NAFLD than the HCV cohort, including inci-
dent HCC; but cardiovascular events and overall mortality were similar in both
groups. Thus, NAFLD seems to have lower rates of liver-related complications but
a similar overall mortality compared with patients with HCV. Fibrosis stage and stan-
dard clinical and biochemical parameters are relevant in assessing the risk of future
liver complications.
HEPATOCELLULAR CARCINOMA IN NONALCOHOLIC FATTY LIVER DISEASE
The exact burden of HCC related to NAFLD remains uncertain, but it is clear that
NAFLD is going to be the most common underlying etiologic risk factor for HCC. In
a population–based study in the United States, NAFLD accounted for 59% of HCC
cases, with a cumulative incidence of 0.3% over a 6-year follow-up.29 The mortality
rates for HCC ranged from 0.25% to 2.3% over 8.3 and 13.7 years of follow-up in 2
further studies.8,9 In the largest prospective community-based study performed soCLD798_proof ■ 3 November 2015 ■ 11:00 am
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354far,30 after a mean follow-up of 7.6 years, only 0.5% patients developed HCC; but the
rate among cirrhotic patients was 10%. As expected, the risk of HCC is more elevated
when examining patients with advanced liver disease; but patients with NAFLD with
HCC have a lower prevalence of cirrhosis than patients with HCC in HCV-related
and other liver diseases. This prevalence is an important characteristic of HCC in
NAFLD, which has been reported in multiple publications (Table 2).
Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis–Related Cirrhosis
Two longitudinal studies on the natural history of NASH-related cirrhosis in the United
States15 and Japan30 confirmed that HCC was the cause of 47% of deaths in patients
with NASH, representing an independent risk factor for liver-related mortality (HR
7.96). Overall, the relative HCC risk and mortality rate in NASH-related cirrhosis seems
to be lower in comparison with viral or alcohol-related cirrhosis. In a large cohort
study, HCC was significantly more common in HCV than NAFLD (6.8% vs 2.4%,
respectively)17 and the HCV cohort had an approximate 0.15% risk per year of HCC
development versus 0.05% in NAFLD. However, the perception that HCC is a rare
and late complication of NAFLD has been denied by recent reports. In North East
England, the overall incidence of HCC increased 1.8-fold from 2000 to 2010; but
most shocking was a more than 10-fold increase in HCC associated with NAFLD, ac-
counting for 34.8% of all the cases in 2010 and making it the single most common un-
derlying cause.39 Not surprisingly, this increasing incidence of HCC was associated
with an increasing prevalence of overweight and obesity (61.0% in 2000 and 65.5%
in 2010). This finding confirms that the apparently lower rates of HCC arising in
NAFLD-cirrhosis compared with other causes of chronic liver disease are definitely
outweighed by the much larger spread of NAFLD in the general population and
open future scenarios in the approach to HCC.
Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Without
Cirrhosis
The most worrisome issue consistently emerging in the last years is the onset of
HCC in patients with NAFLD who do not have cirrhosis yet. A French study analyzed
a cohort of 31 patients with HCC with MetS as the only risk factor for liver disease
and found mild or no fibrosis in most cases, compared with those harboring HCC
associated with an overt cause of liver disease (65% vs 26%, P<.0001).38
The absence of cirrhosis was further confirmed in 38% of Japanese patients41
and in one-third of patients from North East England with NAFLD-related HCC.41
As patients without cirrhosis are not in surveillance programs, most (62.3%) pre-
sented symptomatically with larger tumors, and their median survival was just
7.2 months.39
In conclusion, HCC in NAFLD should not be underestimated for several reasons.
First, once cirrhosis had developed, HCC represents a frequent complication, with
an incidence of up to 10% over a 7-year follow-up. Secondly, HCC can also arise in
the absence of cirrhosis in patients with NASH with multiple metabolic risk factors,
mainly obesity and T2DM. These observations arouse an urgent need to better under-
stand the risk factors linked to the development of HCC, especially in noncirrhotic
livers, and to update screening programs.
Nonalcoholic Fatty Liver Disease in Lean Patients
A small but significant proportion of patients (7%–21%) develops NAFLD despite
normal BMI, and they are defined as lean or normal weight NAFLD.42–46 They are
generally described in the Asian populations; but within the National Health andCLD798_proof ■ 3 November 2015 ■ 11:00 am
Table 2
Principal studies on the association between NAFLD and HCC
Author (Year) Diagnosis Study Population Main Findings
Bugianesi
et al,31 2002
Cirrhosis 641 patients with cirrhosis-associated HCC NAFLD-related features are more frequent in HCC arising in
CC than viral or alcoholic cirrhosis.
Marrero
et al,32 2002
Cirrhosis 105 patients with HCC CC-related HCC was less likely to have undergone HCC
surveillance and had larger tumors at diagnosis.
Regimbeau
et al,33 2004
Cirrhosis 210 patients who underwent resection for HCC Obesity and T2DM may be important risk factors for HCC, via
NAFLD and CC.
Ascha
et al,16 2010
Cirrhosis 510 patients with cirrhosis Patients with NASH cirrhosis have an increased risk of HCC
yearly cumulative incidence (2.6% vs 4.0% in HCV).
Yasui
et al,34 2011
Cirrhosis and
NAFLD/NASH
87 HCC cases; no cirrhosis in 43 patients Most patients with NASH who develop HCC are men with
features of MetS and at a less advanced stage of liver
fibrosis.
Mittal
et al,35 2015
Cirrhosis 1500 patients with HCC NAFLD is the third most common risk factor for HCC. Cirrhosis
was less common in NAFLD-related cases compared with
alcoholic or HCV-related HCC.
Wong
et al,36 2014
Cirrhosis 10,061 adult LT recipients for HCC NAFLD is the most rapidly growing indication for LT in HCC
cases in the United States.
Tateishi
et al,37 2015
Cirrhosis 33,782 patients with HCC (596 NAFLD related) Most cases of nonviral HCC are related to lifestyle factors,
including obesity and T2DM.
Paradis
et al,38 2009
NAFLD/NASH 31 patients with HCCwithMetS as the only risk factor for liver
disease
NAFLD contributes to noncirrhotic HCC.
Dyson
et al,39 2014
Cirrhosis and
NAFLD/NASH
623 patients with HCC HCC cases without cirrhosis most commonly occurred in
NAFLD. Patients without cirrhosis were not in surveillance
programs, andmost presented symptomatically with larger
tumors.
Leung
et al,40 2015
Cirrhosis and
NAFLD/NASH
54 patients with NAFLD-associated HCC HCC can develop in NAFLD without cirrhosis. At diagnosis,
such tumors are larger than those in cirrhotic patients.
Abbreviation: CC, cryptogenic cirrhosis.
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456Nutrition Examination Survey III cohort, 7.4% of subjects had a normal BMI (<25 kg/
m2).47 Lean individuals with NAFLD constitute a subgroup of patients relatively free
from MetS, although insulin resistance can be increased anyway compared with
healthy controls.48 The common variant in the PNPLA3 gene (I148M) can partially
explain the onset of NAFLD in lean patients; but in a recent study,46 PNPLA3 polymor-
phism did not contribute to incident NAFLD.
The pivotal question is whether lean patients with NAFLD have a different disease
progression compared with obese patients with NAFLD, but the answer is still
unknown because of the paucity of clinical and histologic outcome data. In a
biopsy series, leaner Asian patients with NASH were less likely to have advanced
fibrosis and cirrhosis than Caucasians.49 However, the preliminary report of an in-
ternational study indicated a more severe prognosis in lean subjects with biopsy-
proven NAFLD compared with overweight/obese subjects.50 In a cohort of 1090
NAFLD cases, only 125 (11.5%) were classified as lean at first diagnosis. In accor-
dance with previous studies, lean patients with NAFLD were characterized by a
lower prevalence of T2DM, hypertension, hypertriglyceridemia, low high-density li-
poproteins cholesterol, central obesity, and MetS as well as more frequently normal
liver enzymes and a lower prevalence or severity of insulin resistance. Histology
was characterized by milder degrees of steatosis and fibrosis but more severe
lobular inflammation. In a subgroup of 483 patients, whereby the index liver biopsy
had been performed before 2005, the difference in overall mortality between the
lean and nonlean NAFLD group was analyzed. Over a follow-up of 11 years, 71
of the 483 (14.7%) patients died; surprisingly, the cumulative survival was signifi-
cantly shorter in lean patients with NAFLD as compared with non–lean NAFLD
(log-rank test 5 5.6; P<.02). This difference remained significant when adjusted
in a Cox regression model, with only lean NAFLD (HR 11.8; 95% CI 2.8–50.1;
P 5 .001) and age (HR 1.05; 95% CI 1.008–1.1; P 5 .02) identified as prognostic
factors. These provocative data point out that the definition of risk factors for the
progression of NAFLD is still an open issue and that we should not quickly
discharge lean patients with NAFLD from the gastroenterology outpatients clinic,
overlooking their potential liver-related complications.SUMMARY
Patients with NAFLD are at risk of liver-related complications and death; but fibrosis
progression is generally slow, taking around 8 years to progress from stage 0 to
stage 1 fibrosis, although there is a subgroup of rapid progressors who can prog-
ress 3 to 4 stages within 2 to 6 years. There is a prognostic association between
the histologic stage of liver disease and the long-term prognosis of patients with
NAFLD. Currently the presence and severity of fibrosis at index biopsy is the best
indicator of the long-term liver outcome. Pooled data from long-term follow-up
studies of NAFLD demonstrate only approximately 9% of liver-related deaths in pa-
tients without advanced fibrosis or cirrhosis, whereas patients with NAFLD with
advanced fibrosis and cirrhosis demonstrate a 16% mortality with 60% of the
deaths liver related. Among nonhistologic predictors, hypertension and T2DM at
presentation are the factors most consistently associated with the risk of disease
progression that is observed also in lean patients. HCC is a worrisome growing
complication of NAFLD at any stage. Scientific advances in the understanding of
mechanisms of fibrosis and carcinogenesis in NAFLD are awaited with interest in
order to provide clinical indexes to predict and prevent the risk of liver-related
deaths.CLD798_proof ■ 3 November 2015 ■ 11:00 am
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